Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Inventory (2020 - 2026)

RxSight filings provide 6 years of Inventory readings, the most recent being $33.5 million for Q4 2025.

  • On a quarterly basis, Inventory rose 48.22% to $33.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $33.5 million, a 48.22% increase, with the full-year FY2025 number at $33.5 million, up 48.22% from a year prior.
  • Inventory hit $33.5 million in Q4 2025 for RxSight, up from $30.4 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $33.5 million in Q4 2025 to a low of $8.0 million in Q4 2021.
  • Median Inventory over the past 5 years was $18.3 million (2023), compared with a mean of $18.3 million.
  • Biggest five-year swings in Inventory: fell 6.65% in 2021 and later surged 112.8% in 2023.
  • RxSight's Inventory stood at $8.0 million in 2021, then soared by 84.7% to $14.8 million in 2022, then rose by 20.78% to $17.9 million in 2023, then increased by 26.26% to $22.6 million in 2024, then surged by 48.22% to $33.5 million in 2025.
  • The last three reported values for Inventory were $33.5 million (Q4 2025), $30.4 million (Q3 2025), and $25.1 million (Q2 2025) per Business Quant data.